Rein Therapeutics (RNTX) Share-based Compensation (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Share-based Compensation of $156000.0 for Q1 2026, down 40.91% year-over-year from $264000.0 in Q1 2025, and down 39.3% quarter-over-quarter from $257000.0 in Q4 2025.
Rein Therapeutics (RNTX) Share-based Compensation (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Share-based Compensation for 11 consecutive years, with $156000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 40.91% year-over-year to $156000.0; the TTM figure through Mar 2026 stood at $2.1 million (up 72.54% YoY), while the FY2025 annual figure was $2.2 million, down 11.22% from the prior year.
- Share-based Compensation fell to $156000.0 in Q1 2026 per RNTX's latest filing, from $257000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.9 million in Q2 2025 and bottomed at $133000.0 in Q4 2024.
- Historically, Share-based Compensation has averaged $515470.6 across 5 years, with a median of $391000.0 in 2023.
- Annual changes were most pronounced in 2024 — Share-based Compensation plunged 50.74% — and 2025, when it soared 474.85%.
- Rein Therapeutics' Share-based Compensation stood at $424000.0 in 2022, then slumped by 36.32% to $270000.0 in 2023, then slumped by 50.74% to $133000.0 in 2024, then soared by 93.23% to $257000.0 in 2025, then plunged by 39.3% to $156000.0 in 2026.
- Business Quant data shows RNTX's Share-based Compensation at $156000.0 in Q1 2026, $257000.0 in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | - |
| 10 | Rein Therapeutics | 55.53 Mn | 55.53 Mn | - | 1.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.57 Mn |
| Jun 30, 2026 | 1.57 Mn |
| Mar 31, 2026 | 156,000.00 |
| Mar 31, 2026 | 156,000.00 |
| Dec 31, 2025 | 257,000.00 |
| Dec 31, 2025 | 257,000.00 |
| Sep 30, 2025 | 1.45 Mn |
| Sep 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | 264,000.00 |
| Mar 31, 2025 | 264,000.00 |
| Dec 31, 2024 | 133,000.00 |
| Dec 31, 2024 | 133,000.00 |
| Sep 30, 2024 | 508,000.00 |
| Sep 30, 2024 | 508,000.00 |
| Jun 30, 2024 | 326,000.00 |
| Jun 30, 2024 | 326,000.00 |
| Mar 31, 2024 | 525,000.00 |
| Mar 31, 2024 | 525,000.00 |